Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Bioengineering for Optimization of Locoregional Treatment of Advanced Melanoma

Award Number: R01CA292870
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2026
PERIOD OF PERFORMANCE END DATE: 03/31/2031

Group Awards By:

View Award Description

Bioengineering for Optimization of Locoregional Treatment of Advanced Melanoma - Project Summary/Abstract A versatile drug delivery platform of bioadhesive (BNPs) and non-adhesive (NNPs) biodegradable nanoparticles are engineered with unique properties for selective locoregional delivery of cytotoxic and immune conditioning agents to tumor cells, the tumor microenvironment (TME), and tumor draining lymph nodes (DLN). Features of BNPs (e.g. increased tumor retention) and NNPs (e.g. enhanced DLN accumulation) will be leveraged for the optimized locoregional treatment of advanced malignant melanoma. Further innovation in the delivery platform will be engineered by selectively modifying the NP core to enable mRNA incorporation and delivery and improve these therapies for melanoma and other cancers. Using mouse models recapitulating clinical settings of advanced melanoma, we will study comprehensively the induced immunologic effects within the TME and DLN, and abscopal effects on untreated skin tumors and hematogenously-spread metastatic lesions. We hypothesize that a multi-armed strategy of locoregional delivery in pre-clinical models of locally advanced (stage III) and metastatic (stage IV) melanoma—utilizing our next-generation BNPs and NNPs engineered for the efficient delivery of anti-tumor cytotoxic agents in combination with locoregional immune conditioning—will markedly limit melanoma tumor growth while also synergizing with systemic immune checkpoint inhibitors. We will test this hypothesis in three aims: (1) Assess the capacity of intratumoral delivery of BNP-anti-tumor and NNP- immunomodulatory agents to limit melanoma tumors and facilitate anti-melanoma immunity. Specifically, intratumoral delivery of BNP-exatecan, with and without co-delivered NNP-RG108 or NNP-MPLA, which we have engineered to accumulate in DLN and boost anti-tumor responses, will be tested in YUMM1.7-OVA (with tetramer tracking) and YUMMER1.7 melanoma models. We will assess local (TME, DLN) and systemic anti-tumor immune effects, including abscopal effects on a distant untreated tumor. (2) Develop next-generation locoregional immune enhancing BNPs by engineering incorporation of mRNA (IL-12) into the particle core. By engineering poly(amine-co-ester) (PACE) cores, BNP encapsulating IL-12 mRNA will be developed to enhance uptake by local DC populations and compared to lipid nanoparticle delivery. We will measure the degree to which select BNP-cytotoxic/NNP-DLN conditioning combinations can be enhanced by co-delivery with TME conditioning BNP-IL-12 mRNA, and use TotalSeq-C mouse CiteSeq scRNAseq/TCRseq with BaseScope and DBiTseq to identify tumor specific cells, TME transcriptional changes and spatial organization to better understand locoregional strategies. (3) Assess the capacity of systemically administered immune checkpoint inhibition to augment the anti-tumor effects of intratumoral BNP-cytotoxic agents, with and without BNP/NNP co- delivered local immune conditioning agents, to optimally treat melanoma tumors and limit metastatic melanoma. Through completion of these aims, we will advance our control of locoregional therapies for melanoma, and prepare for translation of these technologies to human melanoma patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $610,637 )
2026	2026	YALE UNIV	150 MUNSON ST	NEW HAVEN	CT	06511	SOUTH CENTRAL CT	USA	Cancer Treatment Research	000	1	3/31/2026	NEW	$610,637
														Subtotal = $610,637

Grand Total All Awards = $610,637

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Bioengineering for Optimization of Locoregional Treatment of Advanced Melanoma

Award Number: R01CA292870

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2026

PERIOD OF PERFORMANCE END DATE: 03/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer